{
    "medicine_id": "f172b0383ed060b59fd8def7c57f83200fe7f375",
    "platform_id": "DB06021",
    "metadata": {
        "name": "Reagila 1 5 mg Capsule",
        "composition": "1 5 mg AV 412",
        "clinical_particulars": {
            "therapeutic_indications": "Investigated for use treatment in cancer tumors unspecified",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "NA",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00012",
                        "description": "The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with AV 412"
                    },
                    {
                        "drugbank-id": "DB00016",
                        "description": "The risk or severity of Thrombosis can be increased when Erythropoietin is combined with AV 412"
                    },
                    {
                        "drugbank-id": "DB08894",
                        "description": "The risk or severity of Thrombosis can be increased when Peginesatide is combined with AV 412"
                    },
                    {
                        "drugbank-id": "DB09107",
                        "description": "The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol epoetin beta is combined with AV 412"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}